Gilead’s lenacapavir: HIV prospects strongest in long-acting …
WEBAug 25, 2021 · Gilead’s lenacapavir will find its strongest niche as a long-acting HIV combination treatment, experts said. Manasi Vaidya August 25, 2021. Gilead announced a collaboration with Merck in March to study lenacapavir with islatravir, a nucleoside reverse transcriptase translocation inhibitor (NRTTI), which is also a new drug class in HIV.
Home - Clinical Trials Arena
WEBModerna blamed after children offered £1,500 to take part in Covid-19 trial. Under the EU Clinical Trials Regulation, financial incentives are not allowed for participants under 16 to prevent undue influence. More themes. Artificial Intelligence. Cloud.
About Us Online - Clinical Trials Arena
WEBAbout Us. Clinicaltrialsarena.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone – from senior management through to research and QA ...
Januvia - Treatment of Diabetes Type 2 - Clinical Trials Arena
WEBSep 29, 2009 · Januvia (sitagliptin phosphate) is an antihyperglycaemic drug containing an orally active inhibitor of the dipeptidyl peptidase-IV (DPP-IV) enzyme. Developed by Merck Sharp & Dohme (MSD), a UK subsidiary of Merck & Co, sitagliptin is used for treating type 2 diabetes mellitus. The drug has proved effective in lowering blood sugar levels of ...
Cerevance raises $47m to fund Phase III trial for lead Parkinson’s …
WEBApr 26, 2024 · US-based Cerevance has secured $47m in Series B-1 extension funding to finance the upcoming Phase III trial for its lead therapy, CVN424. The financiers included multiple US-based venture capital firms such as Google Ventures, Agent Capital, Bioluminescence Ventures, and Double Point Ventures. CVN424 is a non-dopamine therapy that inhibits G ...
Treatment for Rheumatoid Arthritis (RA) - Clinical Trials Arena
WEBAug 31, 2010 · Abatacept (Orencia) was developed by Bristol-Myers-Squibb for the treatment of rheumatoid arthritis (RA). It is a biologic drug which contains a selective co-stimulation modulator. The US Food and Drug Administration approved the drug in December 2005, followed by the European Commission in July 2010. In August 2011, the FDA approved a ...
ICON partners with US Government for clinical trials of Covid-19 ...
WEBSep 14, 2023 · ICON’s government and public health solutions team will conduct a Phase IIb active comparator clinical trial to evaluate the efficacy of the next-generation Covid-19 vaccine, selected by BARDA, compared to the currently approved/authorised vaccines.The trial is expected to enrol 10,000 volunteers over a six-month period. Although the Covid-19 trial activity has significantly decreased in the ...
Travere’s sparsentan approvable but could be first-line SOC use in …
WEBJan 27, 2021 · Travere Therapeutics’ sparsentan could replace first-line (1L) standard-of-care (SOC) treatment in newly diagnosed focal segmental glomerulosclerosis (FSGS), some experts said. Manasi Vaidya January 27, 2021. Immunosuppressive therapies including steroids are considered part of 1L SOC treatments in FSGS, but there are no FDA-approved therapies.
Top Ongoing mRNA Herpes Vaccine Trials - Clinical Trials Arena
WEBIn 2023, four major trials in influenza, genital herpes, and melanoma will show just how far-reaching mRNA vaccine technology could be. These include Moderna’s mRNA-1010 and Pfizer’s modRNA vaccine in seasonal influenza, Roche /BioNTech’s RO7198457 in advanced melanoma, and BioNTech’s BNT-163 for lesions in genital herpes.
Russia university completes clinical trials of Covid-19 vaccine
WEBJul 13, 2020 · The trial participants will be monitored on an outpatient basis after being discharged. Last month, Russia granted authorisation for clinical trials of two formulations of the Covid-19 vaccine candidate, which was developed by the Gamaleya National Research Center for Epidemiology and Microbiology. An intramuscular solution of the vaccine was tested at the Burdenko Military Hospital while ...